Retatrutide 8mg
£80.00
Pound sterling (£) - GBP
Retatrutide is an investigational drug developed by Eli Lilly and Company that acts as a triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This unique mechanism of action targets three key hormones involved in regulating appetite, metabolism, and blood sugar control. In clinical trials, retatrutide has demonstrated promising results for weight loss and improvements in various metabolic markers, including liver fat reduction, glycemic control, and blood pressure.Â
Regarding the 8 mg dose of Retatrutide:
- It’s one of the dosages being investigated in clinical trials for weight loss in adults with obesity.
- In phase 2 studies, the 8 mg dose of retatrutide was associated with a significant mean percentage change in body weight at 48 weeks, showing a reduction of 22.8%.
- At 48 weeks, 100% of participants on the 8 mg dose achieved a weight reduction of at least 5%, 91% achieved a reduction of at least 10%, and 75% achieved a reduction of at least 15%.
The 8 mg dose also showed significant reductions in liver fat content, with an average reduction of 81.7% at 48 weeks in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). More than 85% of participants on the 8 mg dose achieved resolution of hepatic steatosis (liver fat content <5%) at week 48.Â
Important to note:
- Retatrutide is currently not approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) and is only available for use in clinical trial settings.
- It’s administered as a once-weekly subcutaneous injection.
- Common side effects reported in trials include gastrointestinal issues like nausea, vomiting, diarrhea, and constipation, which are typically mild to moderate and may be reduced by starting with a lower dose and gradually escalating.
- t’s one of the dosages being investigated in clinical trials for weight loss in adults with obesity.
- In phase 2 studies, the 8 mg dose of retatrutide was associated with a significant mean percentage change in body weight at 48 weeks, showing a reduction of 22.8%.
- At 48 weeks, 100% of participants on the 8 mg dose achieved a weight reduction of at least 5%, 91% achieved a reduction of at least 10%, and 75% achieved a reduction of at least 15%.
We offer complimentary express shipping.
Free returns are available worldwide. If your item is eligible for return, you have 30 days from the date you receive your order to follow this procedure.
See delivery and returns for more information.
Shop The Look
